Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis

被引:17
作者
Poulin, Yves [1 ]
Papp, Kim [2 ]
Bissonnette, Robert [3 ]
Barber, Kirk [4 ]
Kerrouche, Nabil [5 ]
Villemagne, Herve [5 ]
机构
[1] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[2] K Papp Clin Res Inc, Waterloo, ON, Canada
[3] Innovaderm Res Laval Inc, Laval, PQ, Canada
[4] Kirk Barber Res, Calgary, AB, Canada
[5] Galderma Med Affairs, Sophia Antipolis, France
关键词
QUALITY-OF-LIFE; BETAMETHASONE DIPROPIONATE; MAINTENANCE TREATMENT; THERAPY; IMPROVEMENT; OINTMENT; VEHICLE;
D O I
10.3109/09546630903493311
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
We evaluated in this study the efficacy and safety of an alternate regimen using clobetasol propionate 0.05% shampoo (CP shampoo) for long-term control of scalp psoriasis. Patients with moderate scalp psoriasis (Global Severity Score [GSS] of 3 on a 0-5 scale) first received CP shampoo once daily for 4 weeks. Patients with a GSS < 2 were then randomized into the maintenance phase, receiving CP shampoo or vehicle twice weekly. When relapse (GSS > 2) occurred, patients received the 4-week daily CP shampoo treatment. Patients who had a GSS < 2 afterwards reinitiated the twice-weekly maintenance according to the original randomization scheme. Among the 168 patients enrolled, 141 (83.9%) had a GSS < 2 after the initial phase. The median time to first relapse was 141 days with CP shampoo, almost 4 months later than with vehicle (30.5 days;p < 0.0001). After 6 months, the percentage of patients who had no relapse was significantly higher with CP shampoo (40.3%) than with vehicle (11.6%;p < 0.001). CP shampoo was also safe during the 7-month study period, without leading to more cases of skin atrophy, telangiectasia, hypothalamic-pituitary-adrenal (HPA) axis suppression or adverse events compared to vehicle. The alternate treatment regimen with CP shampoo is efficacious and safe for long-term management of moderate scalp psoriasis.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 28 条
  • [1] Clearance is not a realistic expectation of psoriasis treatment
    Al-Suwaidan, SN
    Feldman, SR
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (05) : 796 - 802
  • [2] Andres Philippe, 2006, J Drugs Dermatol, V5, P328
  • [3] Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis
    Brown, Katherine K.
    Rehmus, Wingfield E.
    Kimball, Alexa B.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) : 607 - 613
  • [4] Topical corticosteroid phobia in patients with atopic eczema
    Charman, CR
    Morris, AD
    Williams, HC
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (05) : 931 - 936
  • [5] Quality of life issues in psoriasis
    Choi, J
    Koo, JYM
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (02) : S57 - S61
  • [6] DAWBER R, 1995, HAIR SCALP DISORDERS
  • [7] European patient perspectives on the impact of psoriasis:: the EUROPSO patient membership survey
    Dubertret, L.
    Mrowietz, U.
    Ranki, A.
    van de Kerkhof, P. C. M.
    Chimenti, S.
    Lotti, T.
    Schaefer, G.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (04) : 729 - 736
  • [8] DUVIVIER A, 1975, ARCH DERMATOL, V11, P581
  • [9] Patients' vehicle preference for corticosteroid treatments of scalp psoriasis
    Feldman, SR
    Housman, TS
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2003, 4 (04) : 221 - 224
  • [10] Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations
    Gilbertson, EO
    Spellman, MC
    Piacquadio, DJ
    Mulford, MI
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (02) : 318 - 321